[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07517666":3,"trial-entities:NCT07517666":97,"trial-summary:NCT07517666":101},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":34,"secondary_outcomes":42,"sex":65,"minimum_age":66,"maximum_age":17,"healthy_volunteers":67,"eligibility_criteria":68,"std_ages":80,"locations":83,"central_contacts":93,"overall_officials":94,"references":95,"see_also_links":96},"NCT07517666","05026","Genetic Information for Families After Tumor Testing Study","Genetic Information for Families After Tumor Testing (GIFTT) Study","ENROLLING_BY_INVITATION","2028-03","2026-07","2026-07-29","2026-07-15","Abramson Cancer Center at Penn Medicine","OTHER",false,"The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P\u002FLP) germline variant in a cancer predisposition gene.",null,[19],"Cancer",[],"INTERVENTIONAL","HEALTH_SERVICES_RESEARCH",[24],"NA",{"count":26,"type":27},100,"ESTIMATED",[29],{"type":14,"name":30,"description":31,"armGroupLabels":32},"Interactive Chatbot","The chatbot intervention will provide biological parents the option to complete pre-test education using an interactive chatbot as an alternative to remote counseling with a genetic counselor. This interactive chatbot will provide opportunities for longitudinal educational and information support, reminders for scheduling next steps, and the option to send specific questions to the genetic counseling team.",[33],"Single Arm",[35,39],{"measure":36,"description":37,"timeFrame":38},"Uptake of digital pre-test chatbot","Participant completion of digital intervention as an alternative for pre-test counseling (yes\u002Fno)","6 months from consent",{"measure":40,"description":41,"timeFrame":38},"Uptake of genetic testing","Participant completion of genetic testing (yes\u002Fno)",[43,47,51,54,58,62],{"measure":44,"description":45,"timeFrame":46},"Understanding of Genetic Information","Will be evaluated using an adapted version of the KnowGene Scale, a 16-item scale administered to patients after genetic testing and\u002For genetic counseling to measure their understanding of the health implications of genetic testing results","Change from Baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results",{"measure":48,"description":49,"timeFrame":50},"General anxiety and Depression","Will be measured by the 4-item each short Patient Reported Outcomes Measurement Information System (PROMIS) measures","Change from baseline to within 7 days post-education, and from baseline to 6 months after disclosure of genetic test results",{"measure":52,"description":53,"timeFrame":50},"Reactions to genetic information","Will be measured using an 8-item Impact of Events Scale (IES)",{"measure":55,"description":56,"timeFrame":57},"Satisfaction with genetic services","Will be assessed with a 14-items evaluating satisfaction with genetic services","Within 7 days post-education, and within 7 days after disclosure of genetic test results",{"measure":59,"description":60,"timeFrame":61},"Psychosocial impact of returning genomic findings","Evaluation of distress, uncertainty and positive responses to receipt of genetic test results using 17 items from the MICRA (Multi-dimensional Impact of Cancer Risk Assessment Questionnaire)","Within 7 days after disclosure of genetic test results, and at 6 months after disclosure of genetic test results",{"measure":63,"description":64,"timeFrame":61},"Decisional regret","Evaluated using 5-item validated Decision Regret Scale","ALL","18 Years",true,{"inclusion":69,"exclusion":73,"raw_text":79},[70,71,72],"Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P\u002FLP germline variant in a CPG.","18 years of age or older.","Speak and understand English.",[74,75,76,77,78],"Previous genetic testing for the familial variant.","Communication difficulties such as:","Uncorrected or uncompensated hearing and\u002For vision impairment. Patients who can successfully use clinical assistance devices are not excluded.","Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.","Uncontrolled psychiatric\u002Fmental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks.","Inclusion Criteria:\n\n* Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P\u002FLP germline variant in a CPG.\n* 18 years of age or older.\n* Speak and understand English.\n\nExclusion Criteria:\n\n* Previous genetic testing for the familial variant.\n* Communication difficulties such as:\n\n  * Uncorrected or uncompensated hearing and\u002For vision impairment. Patients who can successfully use clinical assistance devices are not excluded.\n  * Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.\n  * Uncontrolled psychiatric\u002Fmental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks.",[81,82],"ADULT","OLDER_ADULT",[84],{"facility":85,"city":86,"state":87,"zip":88,"country":89,"geoPoint":90},"University of Pennsylvania","Philadelphia","Pennsylvania","19104","United States",{"lat":91,"lon":92},39.95238,-75.16362,[],[],[],[],{"nct_id":4,"conditions":98,"biomarkers":100},[99],"Malignant Neoplasm",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]